CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.

CD79B Y196 mutation also showed a clear trend toward better PFS and OS, although the difference was not statistically significant (PFS: HR = 0.54 [95% CI, 0.18 – 1.69], p = 0.228, OS: HR = 0.27 [95% CI, 0.08 – 0.95], p = 0.064) (Figure S3 ). 3.4 Rapid genotyping of MYD88 L265P and CD79B Y196 mutations by i‐densy We suggest that CD79B Y196 mutation is not only a reliable diagnostic marker combined with MYD88 L265P mutation but also a predictive factor for response to R‐MPV.

also in 7,418 other papers